source
- Camurus receives second complete response letter for acromegaly drug CAM2029; Teva announces workforce reductionsCamurus reported that the FDA issued a second complete response letter for its investigational acromegaly therapy CAM2029, citing issues related to a third‑party manufacturer. The agency’s concern…
- Neion Bio secures $23M Series A to develop egg-based protein platform for biologicsNeion Bio announced it closed a $23 million Series A round that was oversubscribed. The funding will be used to advance its platform that leverages chicken eggs, extracting primordial germ cells f…